Sun Pharmaceutical Recalls Bupropion Hydrochloride Tablets for Dissolution Failures
Sun Pharmaceutical Industries is recalling specific lots of Bupropion Hydrochloride Extended-release Tablets because they failed dissolution specifications and a 18-month stability time point.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which indicates a low risk of adverse health consequences. The failure of dissolution specifications and stability time points represents a quality control issue that may affect drug efficacy but is not associated with immediate serious harm.
Plain-English summary
Sun Pharmaceutical Industries, Inc. is recalling specific lots of Bupropion Hydrochloride Extended-release Tablets, USP (SR), 150 mg. The affected products are available in 60-count, 100-count, and 500-count bottles and are distributed nationwide. The recall was initiated because the tablets failed to meet dissolution specifications and a 18-month stability time point.
The recall covers specific lot numbers and expiration dates ranging from January 2017 to October 2017. The products are prescription-only medications manufactured by Sun Pharmaceutical Ind. Ltd. in India and distributed by Sun Pharmaceutical Industries, Inc. in Cranbury, New Jersey.
Consumers and healthcare providers should check their inventory for the specific lot numbers and expiration dates listed in the official recall notice. If the product matches the recalled lots, it should be returned to the pharmacy or supplier for credit or replacement.
The recalled product
- Product
- BUPROPION HYDROCHLORIDE (BUPROPION HYDROCHLORIDE)
- Brand
- BUPROPION HYDROCHLORIDE
- Manufacturer
- Sun Pharmaceutical Industries, Inc.
- Category
- Drug — Prescription Medication
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- a) 60 count JKP1184A
- exp 2/17
- JKP1576A
- JKP2517A
- JKP2527A
- exp 04/17
- JKP2768A exp 06/17
- KP3895A
- JKP4051A
- exp 08/17
- JKP4052A
- JKP4605A exp 09/17 b) 100 count JKP0702A exp 01/17
- JKP1186A exp 02/17
- JKP2766A
- exp 05/17
- JKP3368A
- JKP3369A exp 06/17
- JKP3419A
- JKP3420A exp 07/17
- JKP4056A
UPCs (2)
- 0347335738865
- 0347335737868
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Sun Pharmaceutical Industries, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · BUPROPION HYDROCHLORIDE
- ModerateBupropion extended release tablets recalled after failing tablet specifications
FDA (Drugs) · 2025-10-29
- HighBupropion Extended-Release Tablets Recalled for Dissolution Failure
FDA (Drugs) · 2024-07-17
- HighFDA recalls Bupropion Hydrochloride tablets for foreign tablet contamination
FDA (Drugs) · 2024-01-17
- ModerateBupropion Hydrochloride Extended-Release Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2023-12-13
- ModerateSun Pharmaceutical Bupropion Extended-Release Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2023-10-25
Same manufacturer · Sun Pharmaceutical Industries, Inc.
See all →- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08
- HighPerampanel Prescription Tablets Recalled for Labeling Mix-up
FDA (Drugs) · 2026-07-01
- HighBudesonide inhalation ampules contain black and brown specks and particles
FDA (Drugs) · 2026-06-17
- SevereDoxorubicin liposome injection vials contain glass particulate matter
FDA (Drugs) · 2026-06-17
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17